Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.78 USD
-0.12 (-3.08%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $3.77 -0.01 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ABUS 3.78 -0.12(-3.08%)
Will ABUS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABUS
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
ABUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
Other News for ABUS
Amgen, Garmin among relative market leaders poised to outperform in coming months: BTIG
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Sets Q2 2024 Financial Results Date
Analysts Have Conflicting Sentiments on These Healthcare Companies: Halozyme (HALO), Arbutus Biopharma (ABUS) and Annexon Biosciences (ANNX)
Arbutus Reports Promising Hepatitis B Trial Results